ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,308.15
1.17%
Dow Jones
39,908.00
0.88%
US Dollar vs MXN
16.684
0.00%
Brent Oil
82.825
0.21%
Bitcoin
66,000.45
-0.39%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. NewLink Genetics Corporation (NLNK)

  7. NewLink Genetics Corporation (NLNK) Noticias

NLNK

NewLink Genetics (NLNK)

NewLink Genetics Corporation
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:NLNK
FechaHoraFuenteTítuloSímboloCompañía
09/06/202016:08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NLNKNewLink Genetics Corporation
02/06/202016:22Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NLNKNewLink Genetics Corporation
01/06/202005:29Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:NLNKNewLink Genetics Corporation
29/04/202015:15Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:NLNKNewLink Genetics Corporation
07/04/202016:59Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NLNKNewLink Genetics Corporation
07/04/202015:45Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:NLNKNewLink Genetics Corporation
01/04/202005:02Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:NLNKNewLink Genetics Corporation
30/03/202017:33Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:NLNKNewLink Genetics Corporation
30/03/202007:00GlobeNewswire Inc.Lumos Pharma Appoints Joseph S. McCracken, DVM, MS to Board of Directors Rick Hawkins, CEO, appointed Chairman of the BoardNASDAQ:NLNKNewLink Genetics Corporation
18/03/202007:00GlobeNewswire Inc.NewLink Genetics Stockholders Approve Merger with Lumos PharmaNASDAQ:NLNKNewLink Genetics Corporation
06/03/202007:14Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:NLNKNewLink Genetics Corporation
03/03/202015:28Edgar (US Regulatory)Annual Report (10-k)NASDAQ:NLNKNewLink Genetics Corporation
28/02/202008:00GlobeNewswire Inc.NewLink Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateNASDAQ:NLNKNewLink Genetics Corporation
18/02/202009:07Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NLNKNewLink Genetics Corporation
14/02/202014:24Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:NLNKNewLink Genetics Corporation
13/02/202015:39Edgar (US Regulatory)Revised Proxy Soliciting Materials (definitive) (defr14a)NASDAQ:NLNKNewLink Genetics Corporation
10/02/202007:32Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (definitive) (defm14a)NASDAQ:NLNKNewLink Genetics Corporation
04/02/202007:04Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prer14a)NASDAQ:NLNKNewLink Genetics Corporation
23/12/201915:05GlobeNewswire Inc.NewLink Genetics Announces Exclusive Worldwide License Agreement with Ellipses Pharma for Development of and Rights to Commer...NASDAQ:NLNKNewLink Genetics Corporation
20/12/201909:09GlobeNewswire Inc.NewLink Genetics Announces FDA Approval of Ebola Vaccine V920 (ERVEBO®)NASDAQ:NLNKNewLink Genetics Corporation
16/12/201907:00GlobeNewswire Inc.NewLink Genetics Responds to Proposal from EvercelNASDAQ:NLNKNewLink Genetics Corporation
13/12/201908:12Edgar (US Regulatory)Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)NASDAQ:NLNKNewLink Genetics Corporation
12/12/201916:31GlobeNewswire Inc.Evercel Announces Rejected Offer to Acquire NewLink GeneticsNASDAQ:NLNKNewLink Genetics Corporation
20/11/201905:39Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (preliminary) (prem14a)NASDAQ:NLNKNewLink Genetics Corporation
12/11/201908:00GlobeNewswire Inc.NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®)NASDAQ:NLNKNewLink Genetics Corporation
06/11/201907:00GlobeNewswire Inc.NewLink Genetics Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateNASDAQ:NLNKNewLink Genetics Corporation
30/10/201907:30GlobeNewswire Inc.NewLink Genetics to Host Its Third Quarter 2019 Conference Call on November 6, 2019NASDAQ:NLNKNewLink Genetics Corporation
21/10/201915:30GlobeNewswire Inc.NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Va...NASDAQ:NLNKNewLink Genetics Corporation
30/09/201915:35GlobeNewswire Inc.NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapi...NASDAQ:NLNKNewLink Genetics Corporation
17/09/201916:05GlobeNewswire Inc.NewLink Genetics Announces FDA Accepts Partnered Biologics License Application (BLA) and Grants Priority Review for Ebola Vac...NASDAQ:NLNKNewLink Genetics Corporation
 Showing the most relevant articles for your search:NASDAQ:NLNK

Su Consulta Reciente

TG
SHF
SNP SchneiderNeureither ...
BIT
F19708
Vontobel Financial Produ...
NASDAQ
SLMVV
BOV
PETRT223
PETRT223 Ex:19,45
UNSW3
PNKETH
Kleros Pinakion
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados